Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs
作者:Richard L. Mackman、Lijun Zhang、Vidya Prasad、Constantine G. Boojamra、Janet Douglas、Deborah Grant、Hon Hui、Choung U. Kim、Genevieve Laflamme、Jay Parrish、Antitsa D. Stoycheva、Swami Swaminathan、KeYu Wang、Tomas Cihlar
DOI:10.1016/j.bmc.2007.05.047
日期:2007.8
(NRTIs), 3'-azido-2',3'-dideoxythymidine (AZT), 2',3'-didehydro-2',3'-dideoxythymidine (d4T), and 2',3'-dideoxythymidine (ddT), were synthesized. The anti-HIV activity against wild-type and several major nucleoside-resistant strains of HIV-1 was evaluated together with the inhibition of wild-type HIV reverse transcriptase (RT). Phosphonomethoxy analog of d4T, 8 (d4TP), demonstrated antiviral activity with
含胸腺嘧啶核苷逆转录酶抑制剂(NRTIs),3'-叠氮基2',3'-二脱氧胸苷(AZT),2',3'-二脱氢-2',3'-二脱氧胸苷(d4T)的膦甲氧基核苷类似物,合成2',3'-二脱氧胸苷(ddT)。与野生型HIV逆转录酶(RT)的抑制作用一起评估了抗HIV-1对野生型和几种主要的抗核苷主要毒株的抗HIV活性。d4T,8(d4TP)的膦氧甲氧基类似物表现出抗病毒活性,其EC(50)值为26 microM,而ddT,7(ddTP)和AZT,6(AZTP)的膦酰甲氧基类似物在浓度升高时均无活性到200 microM。双异丙氧基甲氧羰基(bisPOC)前药分别将7和8的抗HIV活性提高了150倍和29倍,从而确定抗病毒耐药性。与bisPOC PMPA(替诺福韦DF)1相比,K65R RT突变病毒对bisPOC前药7和8的耐药性更高。但是,bisPOC前药7对含有多个胸苷类似物突变(6TAMs)